ENCORE: Amikacin Called Safe, Effective for MAC Lung Disease
The phase 3b ENCORE study has shown that Amikacin liposome inhalation suspension (ALIS) is effective for treating treatment-naive patients with Mycobacterium avium complex (MAC) lung disease. The study demonstrated significant improvements in patient-reported symptoms and culture conversion rates when ALIS was used in combination with azithromycin and ethambutol. These findings suggest that ALIS may provide a valuable treatment option for patients with this challenging condition.
- ▪ALIS is FDA approved for treatment-refractory MAC lung disease and shows promise for treatment-naive patients.
- ▪The study involved 425 participants across 22 countries and demonstrated significant improvements in respiratory symptoms and culture conversion rates.
- ▪Patients receiving ALIS showed a statistically significant improvement in quality of life measures compared to the comparator group.
Medscape files mainly under health. We currently carry 225 of its stories.
Opening excerpt (first ~120 words) tap to expand
ORLANDO, Fla. — Amikacin liposome inhalation suspension (ALIS) is already FDA approved to treat people with treatment-refractory Mycobacterium avium complex (MAC) lung disease, and newly announced results of the phase 3b ENCORE study suggest ALIS also holds promise in treatment- naive patients when administered as part of a combination regimen.Investigators compared patient-reported symptoms and culture conversion rates with ALIS vs an empty liposome comparator, each in combination with azithromycin and ethambutol during a 12-month study, and again 1 month and 3 months after stopping treatment.“The take home message would be using ALIS in treatment- naive patients or upfront therapy looks to be effective in two important measures: how the patient feels and microbiologically, with a very…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
